Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system designed to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which are comprised of sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology Inc.

In a report released today, from Guggenheim reiterated a Buy rating on Nautilus Biotechnolgy, with a price target of $2.50. The word on The Street ...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NAUT	$1.85	-6.57%	247.13K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NAUT	$1.85	-6.6%	247.13K
3
4
5
6

NAUT

NAUT

Dividend Overview

Get Nautilus Biotechnology Inc. Data in Excel

Get Nautilus Biotechnology Inc. Data in Excel